What Is ACE-083?

1. How does ACE-083 work?

Myostatin and activins help restrain muscle growth. Follistatin binds these signaling proteins before they reach their receptors. ACE-083 combines modified human follistatin with the Fc portion of an IgG2 antibody to make a drug with specific tissue-binding properties.

Pearsall and colleagues’ laboratory study found that ACE-083 bound myostatin, activin A, activin B and GDF11. Calling it a “myostatin inhibitor” captures only part of its activity. A ligand trap is a protein that captures these signals outside cells.

ACE-083 was designed to remain near the injected muscle and lose activity after entering circulation. Its affinity for the extracellular matrix, the material surrounding cells, helps explain that local behavior. In mouse experiments, the injected muscles grew and produced more force without evidence of growth in distant muscles.

That design differs from raising growth hormone with ipamorelin or supplying an IGF analogue such as IGF-1 LR3. Shared interest in muscle gain does not make their mechanisms, doses or risks interchangeable.

2. Human trial results: how much muscle growth?

The percentages below refer to individual muscles measured by MRI. The healthy-volunteer result is a change from baseline; the phase 2 figures are adjusted differences between treatment and placebo in percentage change. They should not be ranked as if they came from one experiment.

The rectus femoris is one of the quadriceps muscles. The tibialis anterior runs along the front of the shin and helps lift the foot. A 14.5% increase in one thigh muscle cannot be read as 14.5% more total leg muscle, lean mass or strength.

FSHD is facioscapulohumeral muscular dystrophy, a genetic muscle disease. CMT is Charcot-Marie-Tooth disease, an inherited peripheral nerve disorder. Neither population represents healthy lifters running a hypertrophy program.

3. Why did ACE-083 fail if muscles grew?

Acceleron’s March 9, 2020 announcement reported that the CMT trial met its muscle-volume endpoint but missed functional and quality-of-life endpoints. The company discontinued ACE-083 development. Earlier FSHD results had also failed to support continued development for that disease.

The CMT publication deserves a closer reading than “no strength gains.” Manual testing of foot-lifting strength favored ACE-083 (p = 0.03). The instrument-based force measurement did not reach statistical significance (p = 0.13), and walking outcomes did not improve significantly. A clinician-assigned strength grade and a measured force are different endpoints.

There was also an elbow-strength improvement at one assessment in the FSHD trial, but it did not persist across assessments.

A registry search on September 22, 2026 returned the completed phase 1 study and three terminated phase 2 or extension records. The later publication dates on the papers do not mean the development program restarted. No approved ACE-083 treatment was identified in this review.

4. What does this mean for bodybuilding?

ACE-083 has evidence for local human muscle enlargement. The unanswered questions concern trained users, useful performance, durability and the trade-off against adverse effects. A disease trial’s failure cannot establish that no healthy lifter would respond, but it cannot supply a successful bodybuilding protocol either.

Even “contractile muscle volume” needs careful reading. In the FSHD study, researchers calculated it from total volume and MRI fat fraction. It estimates the non-fat portion of a muscle; it is not a direct measurement of how much force that tissue produces.

For physique claims, ask what was measured. An MRI volume, arm circumference, a DXA lean-mass estimate and a personal-best lift answer different questions. Photos cannot establish which tissue changed or whether the change remains after treatment stops.

The trials reviewed here did not establish added benefit alongside testosterone, HGH, resistance training or a calorie surplus. Combining several interventions also makes it harder to identify which caused a gain or an unwanted effect.

5. Side effects and anti-drug antibodies

The FSHD report describes mostly mild or moderate injection-site reactions and muscle pain. One participant had a probably drug-related partial peroneal nerve injury with sensory symptoms; it resolved with residual, progressively improving weakness. During the blinded phase, anti-ACE-083 antibodies occurred in 11 treated participants (39.3%) versus one placebo participant (3.3%).

An antibody result means the immune system recognized the drug. It does not by itself prove a symptomatic autoimmune disease. These findings do show why local delivery cannot be equated with absence of risk.

The studies do not establish long-term safety for repeated enhancement use. They also cannot tell you whether a retail vial contains the same correctly manufactured protein used in the trials. Identity, biological activity and sterility are separate questions from whether a label says “research use only.”

6. ACE-083 dosage, half-life and lasting gains

The healthy-volunteer trial used one or two doses of 50–200 mg per muscle. The CMT randomized trial studied 240 mg per muscle every three weeks. These are descriptions of research exposure, not validated bodybuilding doses or instructions for injection.

In the phase 1 blood analysis, intact ACE-083 was quantifiable in only 14 of 252 samples from the two tested cohorts, all on the first day. Those data cannot establish a dependable elimination half-life. The three-week dosing interval does not measure clearance.

Eight weeks after the final dose, the highest-dose muscle-volume increases were no longer statistically significant. This does not prove everyone returned to baseline; permanent gains remain unestablished.

7. ACE-083 versus follistatin and IGF-1 DES

ACE-083 is a particular engineered fusion protein. “Follistatin 344” is not another name for it, and a follistatin gene-transfer experiment would test a different intervention again. The structure, delivery and duration of exposure affect what a result can support.

IGF-1 DES also attracts claims about bringing up specific muscles. Its page examines a different evidence base, including altered binding to IGF-binding proteins. ACE-083’s local-growth results cannot be borrowed to prove that DES stays at an injection site, or to claim that a follistatin product reproduces ACE-083.

For tested athletes, WADA’s 2026 list prohibits myostatin-binding proteins such as follistatin under S4.3 at all times. ACE-083’s mechanism falls within that class even though the examples do not name it individually.

8. ACE-083 and muscle retention during GLP-1 treatment

Growing one muscle is a different objective from preserving muscle throughout a period of weight loss. The ACE-083 studies identified here did not test combinations with semaglutide, tirzepatide or retatrutide.

A trial addressing that question would need to compare the same weight-loss treatment with and without ACE-083, then measure body composition, strength, function and adverse events. Local MRI growth alone could not establish the overall benefit.

For readers tracking muscle changes during GLP-1 treatment, keep body weight, body-composition estimates and repeatable strength measurements separate. Record the measurement method and conditions. A change in one number should not silently become a claim about all three.

9. ACE-083 FAQ

• What is ACE-083 used for?

  Acceleron developed ACE-083 for localized muscle weakness in neuromuscular diseases. Its clinical program was discontinued; it is not an established treatment for bodybuilding, recovery or muscle retention during weight loss.

• Is ACE-083 a peptide or a steroid?

  ACE-083 is an engineered protein combining modified follistatin with part of an antibody. It acts on muscle-growth regulators and is not an anabolic steroid.

• Does ACE-083 build muscle?

  Trials found increases in the volume of injected muscles. Whether it offers worthwhile, durable gains for trained lifters remains untested.

• Why was ACE-083 discontinued?

  The phase 2 program did not establish the functional benefits needed to continue development, despite increased muscle volume. Acceleron announced the discontinuation on March 9, 2020.

• What is the recommended ACE-083 dosage for bodybuilding?

  No validated bodybuilding dosage exists. Clinical trial doses were studied in selected participants under medical supervision and do not establish a self-injection protocol.

• What is the half-life of ACE-083?

  The human research does not establish a dependable elimination half-life for planning a cycle. Blood detectability, local tissue exposure and the duration of muscle growth are different measurements.

• Is ACE-083 the same as follistatin 344?

  No. ACE-083 is a specific engineered follistatin fusion protein. Results for that molecule cannot establish the identity, activity or safety of products labeled follistatin 344.

• Can ACE-083 preserve muscle on semaglutide or tirzepatide?

  The studies identified in this review did not test those combinations. Local muscle-volume gains do not establish whole-body muscle retention during GLP-1 treatment.

10. Sources